Health startups and the health economy: count the change, not the round
The UK has thousands of small health and life sciences companies and a health service that says it needs them. Their real effect on the health economy depends on whether anything changes for patients and services, not on how much they raise.
The UK has a large health innovation sector, and most of it is small. The Office for Life Sciences counts 6,500 businesses operating in UK life sciences in 2024/25, across 7,600 companies. Together they employed 306,700 people and generated £125.8 billion of turnover. Medical technology accounts for 59% of the companies and 52% of the jobs. Small and medium-sized enterprises make up 88% of all companies.
The direction is less encouraging. Employment fell 2% on the year and turnover 1%. The statistics are labelled as in development and the method changed in 2023/24, so long-run comparisons need care, but the latest year was not one of growth.
Money is tighter
Investment has cooled too. HSBC Innovation Banking’s venture financing report for 2025 says the UK healthtech market shrank 17% year on year. The BioIndustry Association reported £1.79 billion of venture capital for UK biotech in 2025 across 58 deals, down 13.2%. Biotech and healthtech are different markets, but they point the same way. Fewer rounds mean founders have to show value sooner, and to buyers who are under pressure themselves.
The system says it needs them
The NHS has rarely been clearer that it needs new technology. Lord Darzi’s independent investigation of the NHS in England, published in September 2024, described the service as being in the foothills of digital transformation, called for a major tilt towards technology to unlock productivity, and identified a shortfall of £37 billion in capital investment. The 10 Year Health Plan, published in July 2025, describes the NHS as a technological laggard and commits to expanding NICE’s technology appraisal process to cover devices, diagnostics and digital products.
The need shows in the productivity figures. The ONS estimates that healthcare productivity rose 1.1% in 2024 and 1.0% in 2025, but was still 5.8% below its 2019 level.
But adoption is slow and uneven
The government’s Life Sciences Sector Plan, published in July 2025, is candid about the problem. It says uptake of medicines and medical technologies is seen as highly variable across the NHS, and describes routes to procurement as complicated and locally variable. It reports that in 2024, 33% of MedTech firms said they had removed products from the UK market. It commits to an NHS Innovator Passport for medtech by 2026.
NICE estimates there are around 2 million healthtech products available in the UK, with multiple routes into the NHS. No buyer can assess that many. In practice, a trust or integrated care board will look closely at a handful, and choose the ones that make the clearest case.
The lag between a good idea and normal practice is long. A review in the Journal of the Royal Society of Medicine in 2011 examined the often-quoted claim that research takes an average of 17 years to reach clinical practice. The authors traced the figure back to a small number of estimates and warned that the average hides a great deal of variation. The precise number is less important than the point: useful innovation usually takes years to become standard care.
What the support programmes count
England’s health innovation networks exist to close that gap. For 2025/26 they report almost £1.5 billion of investment leveraged, more than 1,500 jobs created or safeguarded, more than 2,300 innovators supported and more than 2.1 million patients benefiting. The NHS Innovation Accelerator reports that since 2015 its innovations have been adopted by 3,532 NHS organisations and reached 13.1 million patients, with 1,345 jobs and over £246 million of external investment.
These are real figures, and they show real activity. But they are reported by the programmes themselves, and most of them measure the health of the companies: money raised, jobs, organisations signed up. The patient counts are the closest thing to an outcome, and they tell you how many people a product reached, not what changed for them.
What this means: the health economy is not the same as the startup economy. A company can raise money, hire, and sell into dozens of trusts without improving anyone’s health. Its value to the system comes later and further down the line: fewer admissions, quicker recovery, people back at work, staff time released for other patients.
What a startup should be measured on
For founders, the practical point is that the evidence a buyer needs and the evidence of real impact are the same thing. Say what outcome you change and for whom. Measure it before and after, in the setting where you will actually be used, not only in a pilot built around you. Express what it saves in terms a finance director recognises, such as bed days, appointments or staff hours. And show who it reaches: the people with the worst health, or only the ones who were easiest to serve.
For commissioners and investors, the same test applies from the other side. Ask for outcomes before activity. Treat funding raised and contracts signed as signs of momentum, not proof of value.
Startups add to the health economy in two ways. One is direct: jobs, investment and turnover, which the sector statistics capture well. The other runs through the health service: care that works better and people who are healthier as a result. The second is larger, harder to count and the one that justifies the public money and clinical time that adoption takes. The question we would put to any health startup, and to ourselves, is the same one: whose life changed, and how do you know?
- Office for Life Sciences, Bioscience and health technology sector statistics 2024 to 2025, September 2026
- HSBC Innovation Banking, UK Life Sciences and Healthcare Venture Financing Report FY 2025
- BioIndustry Association, UK biotech finishes on high despite challenging 2025, January 2026
- DHSC, Independent investigation of the National Health Service in England (Lord Darzi), September 2024
- DHSC, Fit for the future: 10 Year Health Plan for England, executive summary, July 2025
- ONS, Public service productivity, quarterly, UK: January to March 2026, August 2026
- DSIT, DHSC and Office for Life Sciences, Life Sciences Sector Plan, July 2025
- NICE, The 10 Year Health Plan for the NHS
- Morris ZS, Wooding S and Grant J, The answer is 17 years, what is the question, Journal of the Royal Society of Medicine, 2011
- UCLPartners, Annual impact report 2025-26: health innovation network impact
- Health Innovation East Midlands, Report highlights the scale of innovation and system-wide impact, July 2026
- UCLPartners, Annual impact report 2025-26: NHS Innovation Accelerator
How we made this. We gather official and industry data, analyse it ourselves and write up what we think it means. AI tools help us find sources and draft; every figure is checked by us against the sources listed above. Where we have calculated a share or a change ourselves, the chart or text says so.
More insights.
The high street is a service: what small towns like Beverley and Boroughbridge do that city centres cannot
Market towns and local centres are not smaller versions of city centres. They do a different job for their communities, and councils and BIDs should judge them on footfall, dwell and spend as outcomes of that job.
Data & AIAI in hospitality: what pubs, restaurants, cafés and hotels should use it for
Hospitality uses AI less than almost any other sector, under more cost pressure than most. The opportunity is real, but only if it is judged on staff time, waste and guests, not on the tool.
ResearchPoor health is an economic measure: what the North East shows
Economic inactivity, productivity and local growth are usually treated as economic problems. In the North East of England, the data says they are health outcomes in disguise.
Practical ideas, once a month.
Website, growth and marketing tips for small and growing businesses. No spam, and you can unsubscribe at any time.